AgomAb Therapeutics NV

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases. Its pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 (TGFßR1) for Fibrostenosing Crohn's disease, currently in Phase 2a clinical trials. The company also has AGMB-447, an inhaled small molecule inhibitor of ALK5 for idiopathic pulmonary fibrosis, in Phase 1 trials. Additionally, AGMB-101 is a HGF-mimetic monoclonal antibody that agonizes the MET receptor, showing antifibrotic and regenerative activity in preclinical models. AgomAb operates in the United States and is headquartered in Antwerp, Belgium.

AgomAb Therapeutics NV is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol AGMB. Its securities trade in US Dollars (USD), reflecting its primary market presence in the United States. The company is incorporated in Belgium and headquartered in Antwerp, but its stock is traded on a major US exchange, making it accessible to international investors.

AgomAb Therapeutics NV operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing therapies for immunology and inflammatory diseases. Biotechnology companies like AgomAb use biological processes and molecular biology to create drugs, often targeting specific disease pathways. AgomAb's pipeline includes small molecule inhibitors and monoclonal antibodies, which are typical of biotechnology research and development.

AgomAb Therapeutics NV is headquartered in Antwerp, Belgium, where it was incorporated in 2017. The company primarily serves the United States market, as indicated by its US region classification and Nasdaq listing. Its clinical trials and product development are focused on diseases prevalent in the US, such as Fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis. While based in Europe, AgomAb's operations and target market are centered in the US, leveraging its Nasdaq listing for capital access.

AgomAb Therapeutics' pipeline includes three key product candidates. Ontunisertib (AGMB-129) is an oral gastrointestinal-restricted small molecule inhibitor of ALK5 (TGFßR1) for Fibrostenosing Crohn's disease, currently in Phase 2a clinical trials. AGMB-447 is an inhaled small molecule inhibitor of ALK5 for idiopathic pulmonary fibrosis, in Phase 1 trials. AGMB-101 is a HGF-mimetic monoclonal antibody that agonizes the MET receptor, demonstrating antifibrotic and regenerative activity in preclinical models. These candidates target fibrotic and inflammatory conditions, with a focus on gastrointestinal and respiratory diseases.